This content is accessible only to 2020 ASCRS Virtual Annual Meeting attendees. If you attended the virtual meeting, please log in with the account associated with your virtual meeting registration. To log in, click the teal "Login" button in the upper right-hand corner of this page.
To evaluate the targeted refractive and visual outcomes after implantation of the Light Adjustable Lens (LAL, RxSight) after cataract surgery in patients with prior corneal refractive surgery.
In this single-center, consecutive, retrospective case series, patients with a history of prior corneal refractive surgery (LASIK or PRK) who underwent cataract extraction with implantation of the LAL were included. Primary outcome measures included best corrected acuity (BCVA), uncorrected visual acuity (UCVA), mean manifest refraction spherical equivalent (MRSE), and the number of patients within ±0.5 D and ±1.0 D of refractive target. Data was collected preoperatively and following final postoperative adjustment with the light delivery device (LDD).
This study comprised 20 eyes of 18 patients (with plan to update with additional data prior to presentation). Following the final postoperative adjustment with the LDD, the mean MRSE was -0.23 D, with 75% of eyes within ±0.5 D and 100% within ±1.0 D of refractive target. 100% of eyes achieved UCVA of 20/40 or better, with 87% achieving 20/25 UCVA or better. Data will be updated prior to presentation at the ASCRS 2020 meeting.
The LAL provides excellent refractive and visual outcomes in patients with a history of corneal refractive surgery, who are known to have challenging intraocular lens power calculations. These results suggest the LAL is a favorable option in this patient cohort.